Sept. 5, 2024 — Alba is a new a clinical-grade multimodal co-pilot designed to revolutionize personalized medicine and precision oncology. Using Paige’s Foundation Models, Alba delivers AI-driven patient insights in real-time and marks a significant step toward Artificial General Intelligence (AGI).
Alba integrates computational pathology large vision models (LVMs) with conversational large language models (LLMs). Bringing together multiple AI-driven insights into a single, cohesive solution provides a unique, real-time interactive experience for pathologists, oncologists, multidisciplinary clinical teams and in clinical trials management.
One feature of Alba is its ability to aggregate and summarize patient data from the multiple data sources that exist in hospitals, including Electronic Health Records (EHRs), Laboratory Information Systems (LIS), and Image Management Systems (IMS). By eliminating the need to navigate multiple platforms, Alba allows pathologists to access comprehensive, patient-specific summaries — including prior pathology reports, radiology findings, and patient history — within seconds. This reduces time spent on administrative tasks and enables faster, more informed decision-making.
"Pathologists often struggle with the lack of clinical context essential for reaching a precise diagnosis," said Dr. Juan Retamero, VP of Clinical Diagnostics at Paige. "Alba’s natural language processing capabilities, combined with its integration with other clinical software solutions, provide this critical context, facilitating multidisciplinary collaboration and resolving discrepancies between radiology and pathology. In addition, Alba acts as a digital assistant that can order stains or complete a report, all through voice commands, which can help facilitate routine workflow tasks”.
Alba leverages Paige’s portfolio of clinical-grade AI to analyze all the digital images associated with a case, highlighting areas suspicious for cancer and providing interim case evaluations for expert review. This includes Paige Omniscreen, which uses AI to screen multiple molecular biomarkers from tissue. By integrating clinical, pathological, and biomarker data, Alba consolidates relevant information, supports physicians in providing diagnostic recommendations, and automatically generates pathology reports. These reports can then be reviewed, modified, supplemented, and approved by the pathologist using voice commands, enhancing the overall efficiency of the diagnostic process.
"Integrating multiple AI technologies and capabilities into a single system in this way has the potential to support complex decision making in cancer patients. In the same way that even the best airline pilots rely on co-pilots to gather data and guide decision-making, Alba ensures that clinicians are supported and guided with the most relevant, timely, and comprehensive information,” said Razik Yousfi, CTO and CEO of Paige.
Paige Alba is for research use only (RUO), not for use in diagnostic procedures.
For more information, visit www.paige.ai.
July 03, 2024 
